{"id":3438,"date":"2019-09-05T15:02:12","date_gmt":"2019-09-05T15:02:12","guid":{"rendered":"https:\/\/www.sicklecelldisease.org\/?p=3438"},"modified":"2019-09-05T15:02:12","modified_gmt":"2019-09-05T15:02:12","slug":"gbt-and-scdaa-to-host-8th-annual-sickle-cell-disease-scd-therapeutics-conference","status":"publish","type":"post","link":"https:\/\/www.sicklecelldisease.org\/2019\/09\/05\/gbt-and-scdaa-to-host-8th-annual-sickle-cell-disease-scd-therapeutics-conference\/","title":{"rendered":"GBT and SCDAA to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference"},"content":{"rendered":"

GlobalBlood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) announced that they will host the 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Tuesday, September 10, 2019, at The Westin Washington, D.C. U.S. Representative Robin Kelly, chair of the Congressional Black Caucus Health Braintrust, will deliver the keynote address.
\nTaking place during National Sickle Cell Awareness Month, the SCD Therapeutics Conference will highlight the latest medical advances and future trends in the treatment of patients with SCD. In addition to Rep. Kelly\u2019s keynote address, the program will feature panel discussions and presentations from leading physicians, patient advocates and healthcare policymakers on a range of issues and topics, including the impact of SCD on the brain and cognitive function and hot topics in SCD from the perspective of patients and caregivers. The Conference will also feature updates from the American Society of Hematology Research Collaborative\u2019s SCD Clinical Trials Network and the Sickle Cell Community Consortium, as well as presentations from biopharmaceutical industry leaders.
\n\u201cWe are honored to host, in partnership with the Sickle Cell Disease Association of America, the annual SCD Therapeutics Conference for the third year in a row, as it will bring together patient advocates, opinion leaders and clinical experts,\u201d said Ted W. Love, M.D., president and chief executive officer of GBT. \u201cSupport and collaboration across the broader community is essential as we work together to try to fundamentally transform how SCD is treated. We are optimistic that this year\u2019s Conference will spur important discussions as we continue to pursue our shared mission of making a meaningful difference in the future of SCD care.\u201d
\n\u201cAs co-hosts of the annual SCD Therapeutics Conference, we are thrilled to help advance meaningful discussions aimed at understanding and addressing the needs of the SCD community,\u201d said Beverley Francis-Gibson, B.A., M.A., president and chief executive officer of SCDAA. \u201cIt is necessary that we continue to learn and grow based on the latest advancements that will be discussed at the Conference, in addition to understanding future issues and trends for treating patients with SCD.\u201d
\nThe 8th Annual SCD Therapeutics Conference will feature the following speakers and panelists:<\/p>\n